Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening

Cell

Volumn 170, Issue 3, 2017, Pages 577-592.e10

  McDonald, E Robert ^a,b   de Weck, Antoine ^a,b   Schlabach, Michael R ^a,b   Billy, Eric ^a,b   Mavrakis, Konstantinos J ^a,b   Hoffman, Gregory R ^a,b   Belur, Dhiren ^a,b   Castelletti, Deborah ^a,b   Frias, Elizabeth ^a,b   Gampa, Kalyani ^a,b   Golji, Javad ^a,b   Kao, Iris ^a,b   Li, Li ^a,b   Megel, Philippe ^a,b   Perkins, Thomas A ^a,b   Ramadan, Nadire ^a,b   Ruddy, David A ^a,b   Silver, Serena J ^a,b   Sovath, Sosathya ^a,b   Stump, Mark ^a,b   Weber, Odile ^a,b   Widmer, Roland ^a,b   Yu, Jianjun ^a,b   Yu, Kristine ^a,b   Yue, Yingzi ^a,b   Abramowski, Dorothee ^a,b   Ackley, Elizabeth ^a,b   Barrett, Rosemary ^a,b   Berger, Joel ^a,b   Bernard, Julie L ^a,b   Billig, Rebecca ^a,b   Brachmann, Saskia M ^a,b   Buxton, Frank ^a,b   Caothien, Roger ^a,b   Caushi, Justina X ^a,b   Chung, Franklin S ^a,b   Cortés Cros, Marta ^a,b   deBeaumont, Rosalie S ^a,b   Delaunay, Clara ^a,b   Desplat, Aurore ^a,b   Duong, William ^a,b   Dwoske, Donald A ^a,b   Eldridge, Richard S ^a,b   Farsidjani, Ali ^a,b   Feng, Fei ^a,b   Feng, JiaJia ^a,b   Flemming, Daisy ^a,b   Forrester, William ^a,b   Galli, Giorgio G ^a,b   Gao, Zhenhai ^a,b   Gauter, François ^a,b   Gibaja, Veronica ^a,b   Haas, Kristy ^a,b   Hattenberger, Marc ^a,b   Hood, Tami ^a,b   Hurov, Kristen E ^a,b   Jagani, Zainab ^a,b   Jenal, Mathias ^a,b   Johnson, Jennifer A ^a,b   Jones, Michael D ^a,b   Kapoor, Avnish ^a,b   Korn, Joshua ^a,b   Liu, Jilin ^a,b   Liu, Qiumei ^a,b   Liu, Shumei ^a,b   Liu, Yue ^a,b   Loo, Alice T ^a,b   Macchi, Kaitlin J ^a,b   Martin, Typhaine ^a,b   McAllister, Gregory ^a,b   Meyer, Amandine ^a,b   Mollé, Sandra ^a,b   Pagliarini, Raymond A ^a,b   Phadke, Tanushree ^a,b   Repko, Brian ^a,b   Schouwey, Tanja ^a,b   Shanahan, Frances ^a,b   Shen, Qiong ^a,b   Stamm, Christelle ^a,b   Stephan, Christine ^a,b   Stucke, Volker M ^a,b   Tiedt, Ralph ^a,b   Varadarajan, Malini ^a,b   Venkatesan, Kavitha ^a,b   Vitari, Alberto C ^a,b   Wallroth, Marco ^a,b   Weiler, Jan ^a,b   Zhang, Jing ^a,b   Mickanin, Craig ^a,b   Myer, Vic E ^a,b   Porter, Jeffery A ^a,b   Lai, Albert ^a,b   Bitter, Hans ^a,b   Lees, Emma ^a,b   Keen, Nicholas ^a,b   Kauffmann, Audrey ^a,b   Stegmeier, Frank ^a,b   Hofmann, Francesco ^a,b   Schmelzle, Tobias ^a,b   Sellers, William R ^a,b   more..

^a NOVARTIS PHARMA AG   (Switzerland)

^b NONE   (United States)

Author keywords

cancer dependency; CCLE; DRIVE; functional genomics; RNA interference; synthetic lethality

Indexed keywords

MESSENGER RNA; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR; MULTIPROTEIN COMPLEX; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL LINE; CANCER GENETICS; CANCER THERAPY; CELL LINEAGE; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; FUNCTIONAL GENOMICS; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE INTERACTION; GENE REGULATORY NETWORK; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SCREENING; LETHAL MUTATION; MALIGNANT NEOPLASM; MUTATIONAL ANALYSIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; GENE LIBRARY; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR CELL LINE;

CELL LINE, TUMOR; GENE LIBRARY; GENE REGULATORY NETWORKS; HUMANS; MULTIPROTEIN COMPLEXES; NEOPLASMS; ONCOGENES; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 85026428627     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2017.07.005     Document Type: Article

References (57)

1. Aguirre, A.J., Meyers, R.M., Weir, B.A., Vazquez, F., Zhang, C.Z., Ben-David, U., Cook, A., Ha, G., Harrington, W.F., Doshi, M.B., et al. Genomic copy number dictates a gene-independent cell response to CRISPR/Cas9 targeting. Cancer Discov. 6 (2016), 914–929.
2. Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A.A., Kim, S., Wilson, C.J., Lehár, J., Kryukov, G.V., Sonkin, D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483 (2012), 603–607.
3. Baselga, J., Campone, M., Piccart, M., Burris, H.A. 3rd, Rugo, H.S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K.I., Lebrun, F., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366 (2012), 520–529.
4. Bassik, M.C., Kampmann, M., Lebbink, R.J., Wang, S., Hein, M.Y., Poser, I., Weibezahn, J., Horlbeck, M.A., Chen, S., Mann, M., et al. A systematic mammalian genetic interaction map reveals pathways underlying ricin susceptibility. Cell 152 (2013), 909–922.
5. Bassik, M.C., Kampmann, M., Lebbink, R.J., Wang, S., Hein, M.Y., Poser, I., Weibezahn, J., Horlbeck, M.A., Chang, W., Cheng, J., et al. (2016). shiny: Web Application Framework for R. R package version 0.14.2. http://CRAN.R-project.org/package=shiny.
6. Bernardo, G.M., Bebek, G., Ginther, C.L., Sizemore, S.T., Lozada, K.L., Miedler, J.D., Anderson, L.A., Godwin, A.K., Abdul-Karim, F.W., Slamon, D.J., Keri, R.A., FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 32 (2013), 554–563.
7. Blasco, R.B., Francoz, S., Santamaría, D., Cañamero, M., Dubus, P., Charron, J., Baccarini, M., Barbacid, M., c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19 (2011), 652–663.
8. Bondurand, N., Sham, M.H., The role of SOX10 during enteric nervous system development. Dev. Biol. 382 (2013), 330–343.
9. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490 (2012), 61–70.
10. Cheung, H.W., Cowley, G.S., Weir, B.A., Boehm, J.S., Rusin, S., Scott, J.A., East, A., Ali, L.D., Lizotte, P.H., Wong, T.C., et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 108 (2011), 12372–12377.
11. Coultas, L., Pellegrini, M., Visvader, J.E., Lindeman, G.J., Chen, L., Adams, J.M., Huang, D.C., Strasser, A., Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. Cell Death Differ. 10 (2003), 185–192.
12. Cyr, A.R., Kulak, M.V., Park, J.M., Bogachek, M.V., Spanheimer, P.M., Woodfield, G.W., White-Baer, L.S., O'Malley, Y.Q., Sugg, S.L., Olivier, A.K., et al. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene 34 (2015), 436–444.
13. Dey, P., Baddour, J., Muller, F., Wu, C.C., Wang, H., Liao, W.T., Lan, Z., Chen, A., Gutschner, T., Kang, Y., et al. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542 (2017), 119–123.
14. Downward, J., RAS synthetic lethal screens revisited: Still seeking the elusive prize?. Clin. Cancer Res. 21 (2015), 1802–1809.
15. Flaherty, K.T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L.V., Hassel, J.C., Rutkowski, P., Mohr, P., et al., METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367 (2012), 107–114.
16. Forbes, S.A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C.G., Ward, S., Dawson, E., Ponting, L., et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 45:D1 (2017), D777–D783.
17. Fritsch, C., Huang, A., Chatenay-Rivauday, C., Schnell, C., Reddy, A., Liu, M., Kauffmann, A., Guthy, D., Erdmann, D., De Pover, A., et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol. Cancer Ther. 13 (2014), 1117–1129.
18. Ganoth, D., Bornstein, G., Ko, T.K., Larsen, B., Tyers, M., Pagano, M., Hershko, A., The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat. Cell Biol. 3 (2001), 321–324.
19. Grooteclaes, M.L., Frisch, S.M., Evidence for a function of CtBP in epithelial gene regulation and anoikis. Oncogene 19 (2000), 3823–3828.
20. He, Y.J., McCall, C.M., Hu, J., Zeng, Y., Xiong, Y., DDB1 functions as a linker to recruit receptor WD40 proteins to CUL4-ROC1 ubiquitin ligases. Genes Dev. 20 (2006), 2949–2954.
21. Helming, K.C., Wang, X., Wilson, B.G., Vazquez, F., Haswell, J.R., Manchester, H.E., Kim, Y., Kryukov, G.V., Ghandi, M., Aguirre, A.J., et al. ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat. Med. 20 (2014), 251–254.
22. Hoffman, G.R., Rahal, R., Buxton, F., Xiang, K., McAllister, G., Frias, E., Bagdasarian, L., Huber, J., Lindeman, A., Chen, D., et al. Functional epigenetics approach identifies BRM/SMARCA2 as a critical synthetic lethal target in BRG1-deficient cancers. Proc. Natl. Acad. Sci. USA 111 (2014), 3128–3133.
23. Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Blackwell, K.L., André, F., Winer, E.P., et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl. J. Med. 375 (2016), 1738–1748.
24. Hubert, C.G., Bradley, R.K., Ding, Y., Toledo, C.M., Herman, J., Skutt-Kakaria, K., Girard, E.J., Davison, J., Berndt, J., Corrin, P., et al. Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev. 27 (2013), 1032–1045.
25. Hudson, T.J., Anderson, W., Artez, A., Barker, A.D., Bell, C., Bernabé, R.R., Bhan, M.K., Calvo, F., Eerola, I., Gerhard, D.S., et al., International Cancer Genome Consortium. International network of cancer genome projects. Nature 464 (2010), 993–998.
26. Ishihara, T., Tsuda, H., Hotta, A., Kozaki, K., Yoshida, A., Noh, J.Y., Ito, K., Imoto, I., Inazawa, J., ITCH is a putative target for a novel 20q11.22 amplification detected in anaplastic thyroid carcinoma cells by array-based comparative genomic hybridization. Cancer Sci. 99 (2008), 1940–1949.
27. Jackson, C.L., Bouvet, S., Arfs at a glance. J. Cell Sci. 127 (2014), 4103–4109.
28. Karreth, F.A., Frese, K.K., DeNicola, G.M., Baccarini, M., Tuveson, D.A., C-Raf is required for the initiation of lung cancer by K-Ras(G12D). Cancer Discov. 1 (2011), 128–136.
29. Kim, J., McMillan, E., Kim, H.S., Venkateswaran, N., Makkar, G., Rodriguez-Canales, J., Villalobos, P., Neggers, J.E., Mendiratta, S., Wei, S., et al. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. Nature 538 (2016), 114–117.
30. König, R., Chiang, C.Y., Tu, B.P., Yan, S.F., DeJesus, P.D., Romero, A., Bergauer, T., Orth, A., Krueger, U., Zhou, Y., Chanda, S.K., A probability-based approach for the analysis of large-scale RNAi screens. Nat. Methods 4 (2007), 847–849.
31. Kryukov, G.V., Wilson, F.H., Ruth, J.R., Paulk, J., Tsherniak, A., Marlow, S.E., Vazquez, F., Weir, B.A., Fitzgerald, M.E., Tanaka, M., et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science 351 (2016), 1214–1218.
32. Lupien, M., Brown, M., Cistromics of hormone-dependent cancer. Endocr. Relat. Cancer 16 (2009), 381–389.
33. Marcotte, R., Brown, K.R., Suarez, F., Sayad, A., Karamboulas, K., Krzyzanowski, P.M., Sircoulomb, F., Medrano, M., Fedyshyn, Y., Koh, J.L., et al. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2 (2012), 172–189.
34. Marjon, K., Cameron, M.J., Quang, P., Clasquin, M.F., Mandley, E., Kunii, K., McVay, M., Choe, S., Kernytsky, A., Gross, S., et al. MTAP deletions in cancer create vulnerability to targeting of the MAT2A/PRMT5/RIOK1 axis. Cell Rep. 15 (2016), 574–587.
35. Mavrakis, K.J., McDonald, E.R. 3rd, Schlabach, M.R., Billy, E., Hoffman, G.R., deWeck, A., Ruddy, D.A., Venkatesan, K., Yu, J., McAllister, G., et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. Science 351 (2016), 1208–1213.
36. Mayer, I.A., Abramson, V.G., Formisano, L., Balko, J.M., Estrada, M.V., Sanders, M.E., Juric, D., Solit, D., Berger, M.F., Won, H.H., et al. A phase Ib study of alpelisib (BYL719), a PI3Kα-specific inhibitor, with letrozole in ER+/HER2- metastatic breast cancer. Clin. Cancer Res. 23 (2017), 26–34.
37. McCullough, J., Colf, L.A., Sundquist, W.I., Membrane fission reactions of the mammalian ESCRT pathway. Annu. Rev. Biochem. 82 (2013), 663–692.
38. Muller, F.L., Colla, S., Aquilanti, E., Manzo, V.E., Genovese, G., Lee, J., Eisenson, D., Narurkar, R., Deng, P., Nezi, L., et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488 (2012), 337–342.
39. Munoz, D.M., Cassiani, P.J., Li, L., Billy, E., Korn, J.M., Jones, M.D., Golji, J., Ruddy, D.A., Yu, K., McAllister, G., et al. CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions. Cancer Discov. 6 (2016), 900–913.
40. Nijhawan, D., Zack, T.I., Ren, Y., Strickland, M.R., Lamothe, R., Schumacher, S.E., Tsherniak, A., Besche, H.C., Rosenbluh, J., Shehata, S., et al. Cancer vulnerabilities unveiled by genomic loss. Cell 150 (2012), 842–854.
41. Novetsky, A.P., Zighelboim, I., Thompson, D.M. Jr., Powell, M.A., Mutch, D.G., Goodfellow, P.J., Frequent mutations in the RPL22 gene and its clinical and functional implications. Gynecol. Oncol. 128 (2013), 470–474.
42. Orkin, S.H., Zon, L.I., Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132 (2008), 631–644.
43. Otto, T., Sicinski, P., Cell cycle proteins as promising targets in cancer therapy. Nat. Rev. Cancer 17 (2017), 93–115.
44. Pagliarini, R., Shao, W., Sellers, W.R., Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. EMBO Rep. 16 (2015), 280–296.
45. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006), 3472–3476.
46. Pasqualucci, L., Dalla-Favera, R., The genetic landscape of diffuse large B-cell lymphoma. Semin. Hematol. 52 (2015), 67–76.
47. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W., Smyth, G.K., limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res., 43, 2015, e47.
48. Robinson, M.D., McCarthy, D.J., Smyth, G.K., edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26 (2010), 139–140.
49. Rosenbauer, F., Tenen, D.G., Transcription factors in myeloid development: balancing differentiation with transformation. Nat. Rev. Immunol. 7 (2007), 105–117.
50. Shaffer, A.L., Emre, N.C., Lamy, L., Ngo, V.N., Wright, G., Xiao, W., Powell, J., Dave, S., Yu, X., Zhao, H., et al. IRF4 addiction in multiple myeloma. Nature 454 (2008), 226–231.
51. Shao, D.D., Tsherniak, A., Gopal, S., Weir, B.A., Tamayo, P., Stransky, N., Schumacher, S.E., Zack, T.I., Beroukhim, R., Garraway, L.A., et al. ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens. Genome Res. 23 (2013), 665–678.
52. Theurillat, J.P., Metzler, S.C., Henzi, N., Djouder, N., Helbling, M., Zimmermann, A.K., Jacob, F., Soltermann, A., Caduff, R., Heinzelmann-Schwarz, V., et al. URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell 19 (2011), 317–332.
53. Tracey, W.D., Speck, N.A., Potential roles for RUNX1 and its orthologs in determining hematopoietic cell fate. Semin. Cell Dev. Biol. 11 (2000), 337–342.
54. van der Maaten, L.J.P., Hinton, G.E., Visualizing high-dimensional data using t-SNE. J. Mach. Learn. Res. 9 (2008), 2579–2605.
55. Wee, S., Wiederschain, D., Maira, S.M., Loo, A., Miller, C., deBeaumont, R., Stegmeier, F., Yao, Y.M., Lengauer, C., PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. USA 105 (2008), 13057–13062.
56. Weinstein, J.N., Collisson, E.A., Mills, G.B., Shaw, K.R., Ozenberger, B.A., Ellrott, K., Shmulevich, I., Sander, C., Stuart, J.M., Cancer Genome Atlas Research Network. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45 (2013), 1113–1120.
57. Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S.A., Triola, G., Wittinghofer, A., Bastiaens, P.I., Waldmann, H., Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497 (2013), 638–642.